In this study of neoadjuvant chemotherapy with ruxolitinib, approximately 130 patients were randomized to receive dose-dense neoadjuvant chemotherapy with or without ruxolitinib, followed by interval debulking and finally three more cycles of dose-dense neoadjuvant chemotherapy with or without ruxolitinib. The ruxolitinib group experienced a 3-month difference in progression-free survival.

This interview reviews the implications of three recent studies — KEYNOTE-158, EMPOWER, KEYNOTE-826 — on immunotherapy in cervical cancer. In addition to the compelling connection between cervical cancer and the immune system, and therefore the interest in immunotherapy for cervical cancer, immunotherapy offers some key advantages over chemotherapy in this setting. It benefits patients with previous radiation as much as it benefits patients who are radiotherapy-naïve and it is less associated with the formation of fistulas than chemotherapy.

@thatgaydoctor, MD, a family medicine doctor in Chicago and an advocate for the health of underserved and LGBTQ populations, discusses the two weeks spent in isolation learning about the virus, spreading information across social media, and cautioning people about the routes of transmission, especially among the queer population where it seemed to be spreading rapidly in major cities.

“Just an anesthesiologist.” This retired doctor speaks about the country’s lack of understanding of this medical profession. Why? In a recent survey, the general public was asked whether anesthesiologists are physicians: A full 22% of respondents answered incorrectly and 8% were unsure.

Physicians commonly encounter patients with facial pigmented macules. In this patient, the diagnosis was Carney complex.

Anxiety disorders are among the most common of psychiatric disorders, with estimates suggesting a lifetime prevalence in the US of approximately 32%. But development of new and effective treatments for anxiety disorders has lagged behind new treatments for other conditions such as major depressive disorder, bipolar disorder, and schizophrenia. This article reviews current treatment and their effectiveness, and highlights the emerging new hopefuls.